Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states
BNT162b2 XBB.1.5 vaccine provided significant additional protection for immunocompetent adults against COVID-19-associated hospital admission and emergency department visits during the 2023-2024 fall and winter respiratory virus season. This study is registered on clinicaltrials.gov as NCT06199934.
Authors
- Laura Puzniak (ORCID: https://orcid.org/0000-0001-8697-9683)
- Aimin Zhou (ORCID: https://orcid.org/0000-0003-1015-9966)
- Rajeev M. Nepal (ORCID: https://orcid.org/0000-0001-5536-1450)
- Jazmine Mateus (ORCID: https://orcid.org/0000-0003-0794-6504)
- Santiago M. C. Lopez (ORCID: https://orcid.org/0000-0001-7714-1707)
- Leah J. McGrath (ORCID: https://orcid.org/0000-0002-0312-635X)
- Kathleen M. Andersen (ORCID: https://orcid.org/0000-0003-2670-800X)
- Kristen E. Allen (ORCID: https://orcid.org/0000-0003-1116-6789)
- Thomas M. Porter (ORCID: https://orcid.org/0009-0005-5089-2873)
- Tiange Yu (ORCID: https://orcid.org/0009-0009-8854-7142)
- John M. McLaughlin
Institutions
- Pfizer (United States) (US)
- Genesis Research Institute (JP)
Publication Details
- Journal
- Vaccine
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126881
- Citations
- 8
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 9.46
Funders
- Pfizer